BRAVO, YALDA,BURCH, JASON DAVID,CHEN, AUSTIN CHIH-YU,NAGAMIZO, JOE FRED
申请号：
CA3060554
公开号：
CA3060554A1
申请日:
2018.04.17
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
The present disclosure is directed to novel compounds of Formula I andpharmaceuticallyacceptable salts, solvates, solvates of the salt and prodrugs thereof, usefulin theprevention (e g , delaying the onset of or reducing the risk of developing)and treatment (e g ,controlling, alleviating, or slowing the progression of) of cancer, includingglioblastoma,bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamouscell carcinoma,adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinalcancer, coloncancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma,pancreatic cancer,ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostatecancer The compoundsof the disclosure are selective antagonists of the EP4 receptor and usefultreatmentof various diseases that may be ameliorated with blockade of PGE2-mediatedsignaling
